CLXT Key Statistics, Chart & Performance
The current stock price of CLXT is 6.3 USD. In the past month the price increased by 99.37%. In the past year, price increased by 107.37%.
CLXT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CLXT. When comparing the yearly performance of all stocks, CLXT is one of the better performing stocks in the market, outperforming 97.73% of all stocks.
CLXT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLXT. CLXT has a bad profitability rating. Also its financial health evaluation is rather negative.
CLXT Financial Highlights
Over the last trailing twelve months CLXT reported a non-GAAP Earnings per Share(EPS) of -3.04. The EPS decreased by -289.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CLXT Forecast & Estimates
8 analysts have analysed CLXT and the average price target is 36.98 USD. This implies a price increase of 486.9% is expected in the next year compared to the current price of 6.3.
For the next year, analysts expect an EPS growth of 82.92% and a revenue growth 38.59% for CLXT
CLXT Ownership
CLXT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 387.092B | ||
| AMGN | AMGEN INC | 17.06 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.07 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.48 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.82 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 13.02 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.47 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLXT
Company Profile
Calyxt Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Roseville, Minnesota and currently employs 25 full-time employees. The company went IPO on 2017-07-20. Calyxt, Inc. is a plant-based synthetic biology company. The firm is focused on research and development, including gene editing, plant breeding, and trait development. The company specializes in engineering plant metabolisms. The firm leverages its PlantSpring technology platform to engineer plant metabolism to produce sustainable materials and products for use in helping customers meet. The firm operates through the development and commercialization of products derived from plant cells. Its platform provides plant-based synthetic biology solutions to customers across multiple industries. The firm has engineered plant metabolism into products including soybeans with improved fatty-acid profiles and alfalfa able to be better digested by livestock. Its product pipeline includes hemp, winter oats, and high saturated fat soybeans. Hemp serves a range of varieties of materials science needs, including strengthening plastics and reducing petroleum-based content.
Company Info
CALYXT INC
2800 Mount Ridge Rd
Roseville MINNESOTA 55113 US
CEO: Yves Ribeill
Employees: 25
Phone: 16516832807.0
CALYXT INC / CLXT FAQ
Can you describe the business of CALYXT INC?
Calyxt Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Roseville, Minnesota and currently employs 25 full-time employees. The company went IPO on 2017-07-20. Calyxt, Inc. is a plant-based synthetic biology company. The firm is focused on research and development, including gene editing, plant breeding, and trait development. The company specializes in engineering plant metabolisms. The firm leverages its PlantSpring technology platform to engineer plant metabolism to produce sustainable materials and products for use in helping customers meet. The firm operates through the development and commercialization of products derived from plant cells. Its platform provides plant-based synthetic biology solutions to customers across multiple industries. The firm has engineered plant metabolism into products including soybeans with improved fatty-acid profiles and alfalfa able to be better digested by livestock. Its product pipeline includes hemp, winter oats, and high saturated fat soybeans. Hemp serves a range of varieties of materials science needs, including strengthening plastics and reducing petroleum-based content.
Can you provide the latest stock price for CALYXT INC?
The current stock price of CLXT is 6.3 USD. The price increased by 5.53% in the last trading session.
Does CLXT stock pay dividends?
CLXT does not pay a dividend.
What is the ChartMill technical and fundamental rating of CLXT stock?
CLXT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about CALYXT INC (CLXT) stock?
8 analysts have analysed CLXT and the average price target is 36.98 USD. This implies a price increase of 486.9% is expected in the next year compared to the current price of 6.3.
What is CALYXT INC worth?
CALYXT INC (CLXT) has a market capitalization of 31.33M USD. This makes CLXT a Nano Cap stock.